In its third-quarter earnings report, Swiss drug maker Novartis announced that its net sales have risen by 2%, and net income by 10%, compared to the same period last year. The company credited its biosimilars business as a key factor in its growth.
In its third-quarter earnings report, Swiss drug maker Novartis announced that its net sales have risen by 2%, and net income by 10%, compared to the same period last year. The company credited its biosimilars business as a key factor in its growth.
The company’s biopharmaceuticals earned Novartis $292 million during the quarter, a gain of 9%. The company says that its growth in biologics was attributable in part to sales of biosimilar filgrastim (Zarxio) in the United States and the launches of biosimilar rituximab (Rixathon) and etanercept (Erelzi) in the European Union.
Novartis’ CEO, Joe Jimenez, said in an interview following the announcement of the company’s earnings that the market’s response to the launch of Novartis’ biosimilars has been stronger than anticipated. “We’re seeing some of the customers switching whole patient populations over,” said Jimenez. “The reaction is a bit more robust than what we had expected.”
While Jimenez did not divulge how deep a discount the company was providing for its biosimilars, he indicated that Novartis has been selling its rituximab biosimilar, which is approved for all indications of its reference, at more than a 15% discount to the reference rituximab (Rituxan, MabThera).
Novartis’ announcement of its strong third-quarter sales numbers follows less impressive rituximab figures for reference biologic maker, Roche. Last week, Roche reported that its sales of Rituxan/MabThera had slid by 16% due to European biosimilar competition from Novartis as well as from Celltrion, whose rituximab product, Truxima, has also eroded the reference product’s market share.
Sandoz has previously stated that Rixathon represents 1 of 5 major biosimilar products that its Sandoz division has planned for launch in the coming 4 years. In its look toward the future, Novartis highlighted the fact that Rixathon has been accepted for review by the FDA, and that its adalimumab (Humira) biosimilar is under review by the European Medicines Association.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.